Johnson & Johnson (NYSE:JNJ) Shares Sold by KFG Wealth Management LLC

KFG Wealth Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 5,285 shares of the company’s stock after selling 526 shares during the period. KFG Wealth Management LLC’s holdings in Johnson & Johnson were worth $764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Jamison Private Wealth Management Inc. grew its holdings in shares of Johnson & Johnson by 93.7% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 90,537 shares of the company’s stock valued at $13,093,000 after purchasing an additional 43,790 shares during the last quarter. Asio Capital LLC grew its stake in Johnson & Johnson by 1.4% during the 4th quarter. Asio Capital LLC now owns 34,082 shares of the company’s stock worth $4,929,000 after buying an additional 463 shares during the last quarter. Investment Research & Advisory Group Inc. grew its position in shares of Johnson & Johnson by 1.2% during the fourth quarter. Investment Research & Advisory Group Inc. now owns 15,155 shares of the company’s stock worth $2,192,000 after acquiring an additional 187 shares during the last quarter. Duncan Williams Asset Management LLC increased its holdings in shares of Johnson & Johnson by 42.4% in the 4th quarter. Duncan Williams Asset Management LLC now owns 6,439 shares of the company’s stock worth $931,000 after acquiring an additional 1,916 shares during the period. Finally, Precedent Wealth Partners LLC boosted its stake in Johnson & Johnson by 1.6% during the 4th quarter. Precedent Wealth Partners LLC now owns 7,724 shares of the company’s stock valued at $1,117,000 after purchasing an additional 123 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Stock Down 1.5 %

Shares of Johnson & Johnson stock opened at $150.63 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a 50-day moving average price of $147.81 and a 200 day moving average price of $156.12. The company has a market cap of $362.65 billion, a P/E ratio of 22.65, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.29%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.